drugset / Trial / NCT07272434
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Phase 3
Recruiting
25000 enrolled
MAXVAX Biotechnology Limited Liability Company
Guangdong Center for Disease Prevention and Control · collabHebei CDC ,China · collabHenan Center for Disease Control and Prevention · collabHubei Provincial Center for Disease Control and Prevention · collabHunan Provincial Center for Disease Control and Prevention · collabShaanxi Provincial Center for Disease Control and Prevention · collabShandong Province Centers for Disease Control and Prevention · collabSichuan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
Timeline
- Start
- 2025-10-22
- Primary completion
- 2026-07-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) | Vaccine | 0.5 ml | Intramuscular |